Akèy › Myelom Miltip › Kalifòni
Etid klinik pou Myelom Miltip nan Kalifòni
70 etid pou Myelom Miltip ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
- Baldwin Park23 etid
- Los Angeles17 etid
- San Francisco15 etid
- Irvine13 etid
- Orange9 etid
- Sacramento8 etid
- Santa Monica8 etid
- Mountain View8 etid
- Burbank7 etid
- San Diego5 etid
- Alhambra3 etid
- Newport Beach3 etid
- Roseville3 etid
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- City of Hope National Medical Center /ID# 280273, Duarte
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Sacramento
- Research Site, Santa Monica
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- City of Hope, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- University of California San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05652335A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- City of Hope National Medical Center, Duarte
- City of Hope Irvine Lennar, Irvine
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- UCSF Fresno, Clovis
- City of Hope Duarte, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- City of Hope - Duarte, Duarte
- City of Hope - Lennar, Irvine
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07336472Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Duarte, Duarte
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
- USC Norris Comprehensive Cancer Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Berenson Cancer Center, Los Angeles
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07609940A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- University of California San Francisco, San Francisco
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- University of California San Francisco, San Francisco
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07149857A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Beverly Hills Cancer Center Clinical Research Advisors LLC, Beverly Hills
- UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- Valkyrie Clinical Trials, Los Angeles
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- City of Hope, Duarte
- University of California San Francisco, San Francisco
- Stanford University Medical Center, Stanford
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Duarte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07073547A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- UCSF, San Francisco
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Cedars-Sinai Medical Center /ID# 278238, Los Angeles
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Sutter Auburn, Auburn
- Sutter Alta Bates, Berkeley
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
- ak 19 plis
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
- University of California, San Francisco, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05892393A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
- University of California Davis Comprehensive Cancer Center, Sacramento
Ap rekriteEtid obsèvasyon
Laj 21 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT04314752A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Southern California /ID# 272414, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06953960Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- City of Hope National Medical Center, Duarte
- City of Hope - Lennar Foundation Cancer Center, Irvine
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07555938A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Chao Family Comprehensive Cancer Center UCI, Orange
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06980480A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- City of Hope, Duarte
- Stanford University, Palo Alto
- UCSF, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07075185Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- UC Irvine Health, Orange
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06375044A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Beverly Hills Cancer Center (BHCC), Beverly Hills
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07589634A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Duarte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Los Alamitos
- GSK Investigational Site, Torrance
- GSK Investigational Site, Whittier
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beverly Hills Cancer Center, Beverly Hills
- Clovis Community Medical Center, Clovis
- Community Cancer Institute, Clovis
- ak 9 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Duarte
- Research Site, Irvine
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- Mercy Cancer Center - Carmichael, Carmichael
- Mercy San Juan Medical Center, Carmichael
- ak 9 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- City of Hope, Duarte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, La Jolla
- Research Site, Los Angeles
- Research Site, San Francisco
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Orange
- Research Site, Santa Monica
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- UC Davis Comprehensive Cancer Center, Sacramento
- UCLA Health, Jonsson Comprehensive Cancer Center, Santa Monica
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
Ap rekriteFaz 1
Laj 18 a 85 · Tout sèks · Mizajou Aug 10, 2026 · NCT05887167Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.